How is AI changing clinical trial design and patient stratification?

AI and machine learning — like NetraMark's explainable models — identify patient subgroups and surface signal in the small datasets typical of first-in-human and early-phase trials. bioaccess® pairs AI-informed design with fast, lower-cost Latin American execution and U.S. regulatory anchoring.

From the Global Trial Accelerators™ podcast with Dr. Joseph Geraci (NetraMark): watch the episode.

Where AI helps most in early-phase trials

• Patient stratification and responder identification
• Signal detection in small first-in-human datasets
• Explainable models regulators and clinicians can interrogate
• Trial-design optimization (endpoints, enrichment, sample size)
• Caveat: AI is only as good as data quality and curation

Clinical trial services · FIH CRO